320 related articles for article (PubMed ID: 32296580)
21. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
22. CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma.
Zhao J; Cui X; Zhan Q; Zhang K; Su D; Yang S; Hong B; Wang Q; Ju J; Cheng C; Li C; Wan C; Wang Y; Zhou J; Kang C
Theranostics; 2024; 14(7):2835-2855. PubMed ID: 38773970
[No Abstract] [Full Text] [Related]
23. Furanodienone overcomes temozolomide resistance in glioblastoma through the downregulation of CSPG4-Akt-ERK signalling by inhibiting EGR1-dependent transcription.
Chen L; Liu YC; Zheng YY; Xu J; Zhang Y; Liu WL; Li ZY; Huang GD; Li WP
Phytother Res; 2019 Jun; 33(6):1736-1747. PubMed ID: 31006910
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Liang H; Chen Z; Sun L
Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
[TBL] [Abstract][Full Text] [Related]
25. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
[TBL] [Abstract][Full Text] [Related]
26. miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway.
Li H; Chen L; Li JJ; Zhou Q; Huang A; Liu WW; Wang K; Gao L; Qi ST; Lu YT
J Hematol Oncol; 2018 May; 11(1):70. PubMed ID: 29843746
[TBL] [Abstract][Full Text] [Related]
27. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X
Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123
[TBL] [Abstract][Full Text] [Related]
28. Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma.
Dong J; Peng Y; Zhong M; Xie Z; Jiang Z; Wang K; Wu Y
Eur J Pharmacol; 2023 Jan; 938():175444. PubMed ID: 36462734
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of microRNA-299-5p sensitizes glioblastoma cells to temozolomide via the MAPK/ERK signaling pathway.
Peng Y; He X; Chen H; Duan H; Shao B; Yang F; Li H; Yang P; Zeng Y; Zheng J; Li Y; Hu J; Lin L; Teng L
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30061180
[TBL] [Abstract][Full Text] [Related]
30. Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis.
Ge X; Pan MH; Wang L; Li W; Jiang C; He J; Abouzid K; Liu LZ; Shi Z; Jiang BH
Cell Death Dis; 2018 Nov; 9(11):1128. PubMed ID: 30425242
[TBL] [Abstract][Full Text] [Related]
31. Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma.
Cai T; Liu Y; Xiao J
Cancer Med; 2018 Apr; 7(4):1404-1415. PubMed ID: 29479863
[TBL] [Abstract][Full Text] [Related]
32. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
[TBL] [Abstract][Full Text] [Related]
33. Hsa_circ_0043949 reinforces temozolomide resistance via upregulating oncogene ITGA1 axis in glioblastoma.
Li X; Wang N; Leng H; Yuan H; Xu L
Metab Brain Dis; 2022 Dec; 37(8):2979-2993. PubMed ID: 36301458
[TBL] [Abstract][Full Text] [Related]
34. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
Liu T; Li A; Xu Y; Xin Y
Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175
[TBL] [Abstract][Full Text] [Related]
35. Wnt/β-catenin signaling pathway induces autophagy-mediated temozolomide-resistance in human glioblastoma.
Yun EJ; Kim S; Hsieh JT; Baek ST
Cell Death Dis; 2020 Sep; 11(9):771. PubMed ID: 32943609
[TBL] [Abstract][Full Text] [Related]
36. Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma.
Shang C; Tang W; Pan C; Hu X; Hong Y
Cancer Chemother Pharmacol; 2018 Apr; 81(4):671-678. PubMed ID: 29397407
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Tian T; Mingyi M; Qiu X; Qiu Y
Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
[TBL] [Abstract][Full Text] [Related]
38. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
39. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
Wang HH; Chang TY; Lin WC; Wei KC; Shin JW
Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714
[TBL] [Abstract][Full Text] [Related]
40. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.
Conti S; Vexler A; Edry-Botzer L; Kalich-Philosoph L; Corn BW; Shtraus N; Meir Y; Hagoel L; Shtabsky A; Marmor S; Earon G; Lev-Ari S
PLoS One; 2018; 13(7):e0198627. PubMed ID: 29969452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
